Heron Therapeutics | HRTX - Assets


Heron Therapeutics reported $248.95M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
ALKERMES USD 2.49B 157.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 659.81M 10.31M Sep/2025
ANI Pharmaceuticals USD 1.44B 32.22M Dec/2025
Anika Therapeutics USD 189.44M 1.76M Sep/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
Eisai JPY 1.49T 48.22B Dec/2025
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Heron Therapeutics USD 248.95M 16.86M Sep/2025
Insmed USD 2.26B 96.18M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.26B 32.66M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Surmodics USD 178.56M 1.15M Sep/2024
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Veracyte USD 1.41B 38.23M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025